Entecavir: A Review and Considerations for Its Application in Oncology
Tânia Lourenço, Nuno Vale, Francesca Musumeci · 2023
Read Entecavir: A Review and Considerations for Its Application in Oncology by Tânia Lourenço, Nuno Vale, Francesca Musumeci (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10675314.txt.
Description
A peer-reviewed research article from Europe PMC (2023). Entecavir (ETV) is a drug used as a first-line treatment for chronic hepatitis B (CHB) virus infection because it is a guanosine nucleoside analogue with activity against the hepatitis B virus polymerase. The ETV dosage can range from 0.5 mg to 1 mg once a day and the most common side effects include headache, insomnia, fatigue, dizziness, somnolence, vomiting, diarrhea, nausea, dyspepsia, and increased liver enzyme levels.
Catalog record
| CREATOR | Tânia Lourenço, Nuno Vale, Francesca Musumeci |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |